LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Catalyst Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

22.81 -1.72

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.73

Max

23.04

Pagrindiniai rodikliai

By Trading Economics

Pajamos

801K

57M

Pardavimai

-399K

141M

P/E

Sektoriaus vid.

14.981

50.857

Pelnas, tenkantis vienai akcijai

0.68

Pelno marža

40.119

Darbuotojai

181

EBITDA

526K

73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+43.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-142M

2.9B

Ankstesnė atidarymo kaina

24.53

Ankstesnė uždarymo kaina

22.81

Naujienos nuotaikos

By Acuity

50%

50%

170 / 381 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-18 17:32; UTC

Pagrindinės rinkos jėgos

Lion Group Shares Climb on $600 Million Loan for Crypto Treasury

2025-06-18 23:55; UTC

Įsigijimai, susijungimai, perėmimai

Nippon Steel: To Book Restructuring Loss Related to This Sale in 1Q

2025-06-18 23:53; UTC

Įsigijimai, susijungimai, perėmimai

Nippon Steel: NS Kote Is an Entity That Owns All of Company's Equity Stake in AM/NS Calvert

2025-06-18 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nippon Steel: To Book About Y230B Loss Related to Sale of NS Kote to ArcelorMittal

2025-06-18 23:50; UTC

Rinkos pokalbiai

Australian Uranium Stocks Tipped to Go Higher -- Market Talk

2025-06-18 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

2025-06-18 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-06-18 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2025-06-18 23:07; UTC

Rinkos pokalbiai

Fletcher Building Recovery May Be More Muted Than Thought -- Market Talk

2025-06-18 23:00; UTC

Rinkos pokalbiai

Smart Glasses Seen as Possible Future Agentic AI Platform -- Market Talk

2025-06-18 21:50; UTC

Rinkos pokalbiai

Argentina Poised To Become Significant LNG Exporter, Rystad Says -- Market Talk

2025-06-18 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-18 20:38; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Steel and Nippon Finalize Their 'Partnership.' What Comes After the Merger. -- Barrons.com

2025-06-18 20:32; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, Marvell, Sunrun, Nucor, Circle Internet, Korn Ferry, GMS, and More -- Barrons.com

2025-06-18 19:59; UTC

Rinkos pokalbiai

Oil Edges Up as Next Steps in Iran Conflict Eyed -- Market Talk

2025-06-18 19:42; UTC

Rinkos pokalbiai

Natural Gas Extends Gains for Fourth Session -- Market Talk

2025-06-18 19:40; UTC

Uždarbis

Fed Holds Rates Steady and Keeps Door Open to Cuts -- 3rd Update

2025-06-18 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Railroads Have Slashed Costs and Raised Prices. Why One CEO Now Favors a Merger. -- Barrons.com

2025-06-18 18:33; UTC

Rinkos pokalbiai

Fitch Says U.S. Fiscal Outlook Remains Challenging -- Market Talk

2025-06-18 18:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-18 18:26; UTC

Rinkos pokalbiai

Nucor, Steel Dynamics Seen Diverging In Approach To Current Business Climate -- Market Talk

2025-06-18 18:15; UTC

Rinkos pokalbiai

Gold Stays Flat After Fed Decision -- Market Talk

2025-06-18 17:42; UTC

Įsigijimai, susijungimai, perėmimai

ArcelorMittal Expects Related 2Q Gain of About $1.5B

2025-06-18 17:40; UTC

Įsigijimai, susijungimai, perėmimai

ArcelorMittal Completes Acquisition of Nippon Steel's 50% Interest in AM/NS Calvert

2025-06-18 17:20; UTC

Uždarbis

Credit Card Annual Fees Are Going Up. What It Means for the Stocks. -- Barrons.com

2025-06-18 16:52; UTC

Rinkos pokalbiai

Trump Awakens Canada On Need For Fewer Trade Barriers, Macklem Says -- Market Talk

2025-06-18 16:31; UTC

Įsigijimai, susijungimai, perėmimai

Nippon Steel Completes Purchase of U.S. Steel After Reaching Security Deal With Trump Administration -- Update

2025-06-18 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-18 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-18 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Catalyst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

43.54% į viršų

12 mėnesių prognozė

Vidutinis 33.33 USD  43.54%

Aukščiausias 35 USD

Žemiausias 31 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Catalyst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 24.28Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

170 / 381 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.